Tumor and serum levels of murine IL-12.

Slides:

Advertisements

Similar presentations

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Antitumor activity of BAY in patient-derived tumor models.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Activity of MAC-321 (i. v. and p. o

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Risk of PTC associated with serum concentrations of TSH and thyroid hormones among females, stratified by tumor size. *, Conditional logistic regression,

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

Immunohistochemical analyses of SHH expression levels in nonmalignant prostate and adenocarcinoma tissues. Immunohistochemical analyses of SHH expression.

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

The expression of SPINDLIN1 in cancer tissues.

Expression analysis of IGFBP-3 using human whole-genome microarray.

Change in antibody-dependent cellular cytotoxicity between baseline and day 15, day 30, and day 45 for cohort 1 and 2 versus cohort 3. Change in antibody-dependent.

Variation in dUTPase expression in cell lines.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

PTENP1 sensitizes renal cancer cells to chemotherapy.

A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.

Expression profile of RSPO1 and 2 in gastric cancer.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

Interaction of MAPJD with E-box sequence of the RIOK1 gene.

Combination effect of AdTOP-PUMA and chemotherapeutic agents in colon cancer cells. Combination effect of AdTOP-PUMA and chemotherapeutic agents in colon.

Simulations to guide drug design strategies for anti–Bcl-2 therapy.

IL6 mRNA is not detected in metastatic prostate cancer cells.

Cytokine expression in the ileum and colon.

Characterization of the NF-κB activation by anginex.

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

CAT displays very high in vivo stability as exemplified by a rat PK study. CAT displays very high in vivo stability as exemplified by a rat.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Drug sensitivities of IGROV1 cells to AGF94 and PMX at leucovorin (LCV) concentrations of 2 and 25 nmol/L. Drug sensitivities of IGROV1 cells to AGF94.

Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced cytotoxicity in MCF-7 cells. Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced.

Immunohistochemical detection of nuclear and cytoplasmic YB-1 in osteosarcoma and synovial sarcoma. Immunohistochemical detection of nuclear and cytoplasmic.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

GA reduces the growth of Caki-1 tumor xenografts.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

Src expression in a panel of human TCC cell lines.

Antitumor effects of celastrol in vitro and in vivo.

Colony formation of K-562 cells after 24 h (upper panel) or 48 h (lower panel) exposure to ErPC3 (20 μm) and ASO-bcr (10 μm), respectively. Colony formation.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

Discovered and replicated positive correlation between miR-193b

Effect of anti-cyCD79b (10D10) and anti-cyCD79b (10D10)-MCC-DM1 on cytokine levels in cynomolgus monkeys. Effect of anti-cyCD79b (10D10) and anti-cyCD79b.

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Micrographs.

Xenograft regrowth studies.

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

The effect of different concentrations of WMC-79 and time of exposure on the growth of HCT-116 cells. The effect of different concentrations of WMC-79.

Effect of hydrogen peroxide on survival and transcriptional activation of TFF1 in established cell lines from the following human tumor tissues: breast.

PC-3 (A) and DU-145 (B) cell survival analysis by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay following 48 h treatment with 0 μmol/L.

A, P causes G2-M arrest with apoptosis in asynchronous population of PC-3 when exposed to 1.5 and 5 μmol/L P for various time points. A, P

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression. SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression.

A, tumor growth studies in H1975 tumor–bearing mice.

Number of identical D-loop DNA clones detected in 10 DNA clones derived from liver tumor tissues. Number of identical D-loop DNA clones detected in 10.

CRA inhibits the growth of human tumor xenografts in vivo.

Representative photograph of somatic mutations detected by PCR-SSCP.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Only IFNγ shows consistently increased mRNA expression in mycosis fungoides (MF) lesions. mRNA expression levels of various cytokines in the skin of healthy.

VEGF165 stimulates migration of HMVECs

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated.

AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. A,

miR-181a knockdown inhibits VEGF and MMP1 secretion in vitro.

Loss of NQO1 expression inhibits invasion of NSCLC

Presentation transcript:

Tumor and serum levels of murine IL-12. Tumor and serum levels of murine IL-12. Murine IL-12 (mIL-12) levels were measured in the serum (□) and homogenized tumor samples (•) using ELISA at various time points. The units were picogram per milliliter for the serum and picogram per milligram for the tumor. Horizontal line, lower limit of detection of IL-12 in this assay. A, 109 pfu/tumor; B, 1010 pfu/tumor; C, 1011 pfu/tumor. Farzan Siddiqui et al. Mol Cancer Ther 2007;6:380-389 ©2007 by American Association for Cancer Research